Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to
receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the
development and progression of COVID-19 after high-risk exposure to a person with confirmed
SARS-CoV-2 infection.